LP
ZYNE

LMR Partners’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

LMR Partners’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-14,598
Closed -$48K – 659
2020
Q3 		$48K Sell
14,598
-2,576
-15% -$9.46K ﹤0.01% 390
2020
Q2 		$58K Buy
+17,174
New +$81.2K ﹤0.01% 525
2018
Q3 		– Sell
-32,047
Closed -$312K – 541
2018
Q2 		$312K Buy
+32,047
New +$328K 0.02% 343

Other funds holding ZYNE

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

LMR Partners's ZYNE Position: Q4 2020 in Review

LMR Partners sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q4 2020, closing a stake of 14,598 shares — an estimated $48K sold.

LMR Partners first reported a position in ZYNE in Q2 2018 and held it in 3 quarters. The position peaked at $312K in Q2 2018. 58 funds tracked by Wall St. Rank hold ZYNE as of Q4 2020.

  • LMR Partners reported no remaining Zynerba Pharmaceuticals, Inc position as of Q4 2020 after selling out during the quarter.
  • LMR Partners sold 14,598 Zynerba Pharmaceuticals, Inc shares in Q4 2020, an estimated $48K.
  • LMR Partners first reported a position in Zynerba Pharmaceuticals, Inc in Q2 2018 and held it in 3 quarters.
  • LMR Partners's Zynerba Pharmaceuticals, Inc position peaked at $312K in Q2 2018.
  • 58 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2020.

Based on LMR Partners's 13F filing for Q4 2020, filed 16 Feb 2021.